SOMERSET, N.J., March 30 /PRNewswire-FirstCall/ -- Ventiv Health, Inc. , announced today that it will host a discussion titled “Pharmaceutical Business Implications of the Medicare Modernization Act of 2003" on Monday April 11, 2005 from 10:00 A.M. - 1:00 P.M. at the Marriott Hotel in Somerset, New Jersey. The educational session, to be led by John McManus, Former Staff Director of the Ways and Means Health Subcommittee, will focus on Part D, or the Pharmacy benefit segment of the Medicare Modernization Act, which goes into effect in 2006.
As Staff Director of the Ways and Means Health Subcommittee, John McManus led the negotiations and drafted the legislation for the Medicare Prescription Drug Implementation Modernization Act of 2003. During his tenure in the U.S. House of Representatives he also negotiated and drafted the legislation for the Medicare Modernization and Prescription Act of 2002. Today he serves as President and CEO of The McManus Group, where he is responsible for providing strategic policy and political counsel and analysis to health care and tax clients regarding legislative issues before Congress and regulatory issues before the Department of Health and Human Services and the Department of Treasury.
The half-day program will consist of a one-hour discussion on the recent Medicare legislation followed by a working question and answer session. The event is open to pharmaceutical and biotech industry executives. Individuals interested in attending this event should contact Diane Randise at (732) 537-4888 by Thursday, April 7th.
About Ventiv Health
Ventiv Health, Inc. is the leading provider of late-stage clinical, sales, marketing and compliance solutions to pharmaceutical and biotech companies. Ventiv is a multi-disciplinary company with a singular focus on providing excellence in customized solutions across the full spectrum of services combining both integrated and independent programs. Ventiv’s approximately 4,000 employees support over 75 client organizations, including the world’s Top 20 pharmaceuticals companies as well as emerging and specialty biotech leaders. For more information on Ventiv Health, visit http://www.ventiv.com/.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause Ventiv Health’s performance to differ materially. Such risks include, without limitation: changes in trends in the pharmaceutical industry or in pharmaceutical outsourcing; our ability to compete successfully with other services in the market; our ability to maintain large client contracts or to enter into new contracts; uncertainties related to future incentive payments; and, our ability to operate successfully in new lines of business. Readers of this press release are referred to documents filed from time to time by Ventiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.
Ventiv Health, Inc.
CONTACT: Investors-Media: Kellie Walsh of Lazar Partners Ltd.,+1-212-867-1762, kwalsh@lazarpartners.com, for Ventiv Health, Inc.;Conference: Diane Randise of Ventiv Health, Inc., +1-732-537-4888
Web site: http://www.ventiv.com/